These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 17159460

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.
    Leal A, Rosillon D, Mehnert A, Jarema M, Remington G.
    Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):811-6. PubMed ID: 15386706
    [Abstract] [Full Text] [Related]

  • 63. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A.
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
    Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R.
    Int J Clin Pharmacol Ther; 2008 Jan; 46(1):14-22. PubMed ID: 18218293
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Gender-specific effects in the treatment of acute schizophrenia with risperidone.
    Raedler TJ, Schreiner A, Naber D, Wiedemann K.
    Pharmacopsychiatry; 2006 Sep; 39(5):171-4. PubMed ID: 16944407
    [Abstract] [Full Text] [Related]

  • 75. [Improvement criteria after neuroleptic treatment and clinical and neuroradiological factors in schizophrenic psychoses. Preliminary studies].
    Jarema M, Choma M, Poniatowska R, Krawczyk R, Kozłowski P.
    Psychiatr Pol; 1997 Sep; 31(1):21-32. PubMed ID: 9527652
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR.
    Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.